Bone marrow-derived mesenchymal stromal cells (BM-MSC) have been used to treat steroid refractory acute GVHD, but there are indications that stromal cells isolated from term placental tissue have a stronger immunosuppressive effect in vitro. Unlike BM-MSC, these cells are accessible with non-invasive procedures and require little or no ethical consideration. We have isolated stromal cells from term fetal membrane (FMSCs), umbilical cords (UCSCs), and placental villi (PVSCs) as well as from bone marrow and compared their immunoregulatory capacity in allogeneic settings. Peripheral blood mononuclear cells (PBMC) from at least 16 donors were stimulated with irradiated allogeneic PBMC in mixed lymphocyte reactions (MLRs) in the absence or presence of stromal cells (stromal cells/PBMC ratio 1:10). FMSC showed the strongest and most consistent suppression (median 47% suppression, P\0.0001) compared to UCSCs (29%, P 5 0.015) and BM-MSCs (41%, P 5 0.014), whereas PVSCs showed poor suppressive capacity. We further found that crude preparations of unseparated fetal membrane generated stromal cells that were at least as good at depriving proliferation compared to cells isolated from separated amniotic or chorionic membranes. When the FMSC were pre-cultured for 48h in MLR supernatants, the inhibiting effect on proliferation of the MLR cultures was increased (P 5 0.031). FMSC also reduced proliferation of T-cells when added to cultures of anti-CD3 and -CD28 stimulated purified CD3+ cells (median 49% suppression). When added to MLR cultures, FMSCs suppressed the production of IFN-g and IL-17 (P 5 0.0013 and P 5 0.03, respectively), but promoted the secretion of IL-10 (P 5 0.0071). In this setting, BM-MSCs had no significant effect on secretion of IFN-g, IL-17, or IL-10. Surface expression analysis with flow cytometry showed that FMSCs had a higher expression of adhesion molecules ICAM-1, CD29 (b1), and CD49d (a4) (P\0.05), and of the negative costimulatory marker PD-L1 (P\0.05), compared to BM-MSC. Both FMSC and BM-MSC showed high expression of PD-L2. To conclude, FMSC may have therapeutic potential in inflammatory disorders such as GVHD, as they greatly suppress T-cells in allogeneic settings and express high levels of integrins that are of importance in homing to inflamed tissues.
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A matched cohort analysis was performed comparing patients in a Phase I dose-escalation trial evaluating maximum-tolerated single or repeated dose of allogeneic MultistemÒ, an adherent multipotent adult progenitor cell (MAPC) product, with a control population undergoing HSCT without MAPC administration. Patients surviving at least 50 days post-HSCT without relapse were eligible for analysis, and matched with a control cohort by disease and transplant characteristics. Time to neutrophil (ANC $500/ul for 3 consecutive days) and platelet (sustained platelets $50,000 without transfusion) engraftment, as well as total bone marrow cellularity after HSCT on days 28 and 100 by blinded double pathologist independent review, were assessed. Unpaired t test was applied to compare days of engraftment and marrow cellularities.
23 patients undergoing conventional ablative allogeneic HSCT with MAPC exposure in addition to their matched pair allogeneic HSCT recipients were eligible for analysis (Table 1 ). The median time to neutrophil engraftment was significantly shortened among patients receiving MAPC, compared to control patients, occurring at day 14 (range 11-23) and 17 (range 13-23), respectively (p 5 0.016). There was no significant difference in time to platelet engraftment. In 16/23 (70%) and 10/14 (71%) evaluable patients receiving MAPC, total marrow cellularity was $ control patients at days 28 and 100. There was a trend towards significantly increased marrow cellularity at these time points among recipients of MAPC (p 5 0.077 and p 5 0.061).
The infusion of MAPC progenitors in patients receiving allogeneic HSCT is associated with a shorter time to neutrophil engraftment. Total bone marrow cellularity at days 28 and 100 appears enhanced among patients receiving MAPC. These preliminary findings support further analysis of a role for infused MSC in facilitating bone marrow recovery in the HSCT-setting. , are an immune-modulatory, bone marrow-derived adult adherent allogeneic stem cell product that can be manufactured to large scale. This provides consistency of universal donor stromal cell therapy product during clinical studies. Pre-clinical studies showed safety of IV infusion and survival benefit in a haploidentical acute GVHD rodent models (Kovacsovics 2008 , 2009 , Metheny, 2011 . Methods: This is an open label Phase I clinical dose escalation study with the primary goal to assess safety of MultiStem as an adjunct therapy for adult hematological malignancy patients shortly after allogeneic HSCT. Patients were enrolled for stromal cell administration as a single dose or in multiple weekly doses. Infusional toxicity and RRTs was assessed for 30 days following the last dose. Secondary endpoints included incidence of acute GVHD, infection and survival through day 100. Dose escalation was guided by the Continual Reassessment Method (CRM).
Results: Enrollment was completed for the target of 36 patients from 5 clinical centers for this Phase I clinical trial. 18 patients received a single dose MultiStem IV at 1, 5, or 10 million cells per kg at day 2 and 18 patients received MultiStem IV at 1 or 5 million cells per kg at days 2, 9 and 16 or days 2, 9, 16 and 30 after allogeneic HSCT. There was no observed infusional toxicity in either arm. Two patients in the single dose arm experienced Bearman RRTs (Grade 3 mucositis; Grade 3 renal and pulmonary failure). These events were deemed unrelated to study product. In the multi-dose cohort, one patient experienced liver GVHD, deemed possibly related to study product. Engraftment occurred in all 36 patients and the median time to neutrophil engraftment was 15 days (range, 11-25 days). The 100-day cumulative incidence of Grade II-IV and III-IV GVHD was 28% and 6%, respectively in the single dose arm. Preliminary evaluations of the repeat dose arm showed 21% and 11% Grade II-IV and III-IV GVHD, respectively. The highest tested single and repeat dose regimens showed the lowest GVHD frequencies.
Conclusion: Single dose and repeat dose administration of Multi-Stem is well-tolerated, without observation of infusional toxicity or graft failure. The observed low incidence of severe acute GVHD supports the concept that this stromal stem cell therapy product is safe and can be harnessed as a novel therapeutic option for GVHD prophylaxis following HSCT. Organs involved in aGVHD were skin (67%), GI-tract (83%) and liver (28%). Overall grade was II for 22%, III for 72%, and IV for 6% patients. 1 patient received one infusion, all other patients received two or more infusions. Median follow-up was 5.5m (range 0.33-12). Complete response was observed in 11 patients 61%, after a median of 65 days (range 10-184 days). The OS was significantly better in responders when compared to non-responders (p \0.001). Of the 11 patients who reached a CR, 8 patients relapsed approximately 2 months after reaching CR (median 59 days, range: 1-244). Three children relapsed with clinical signs of an alloimmune-lung, auto-immune-cytopenia or limited cGVHD and all 5 adults relapsed with GVHD of the gut (median 98 days after reaching CR, range: 35-302 days). However, GVHD of the gut was then again sensitive to steroids. Overall, 7 patients died, 4 due to progression of aGVHD, 1 patient due to abdominal bleeding and 2 due to sepsis. Extensive biomarkeranalysis were performed. We found biomarkers who are associated with clinical response of patients. Conclusion: Generation and infusion of MSCs in steroid-resistant aGVHD grade II-IV is feasible, safe and very effective. In addition, also patients who initially responded to MSCs but develop later a relapse of aGVHD during tapering or cessation of immunosuppressive drugs become again sensitive to the treatment with steroids. Clinical response can be predicted by biomarkers.
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IN SEARCH FOR MOLECULES INVOLVED IN THE IMMUNOSSUPRESSION INDUCED BY MESENCHYMAL STROMAL CELLS
Du Rocher, B. 1,2 , Mencalha, A. 1,2 , Binato, R. 1,2 , Dutra, T. 1,2 , Bouzas, L.F. 1 , Abdelhay, E. 1,2 1 Instituto Nacional de Cancer, Rio de Janeiro, Brazil; 2 Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil Background: Mesenchymal stromal cells (MSCs) improve hematopoietic recovery, contribute to tissue regeneration and posses immunosuppressive properties. Because of these unique properties their applicability in the bone marrow transplantation has attracted much attention, especially as a promising therapy to control graftversus-host disease. In this way, a better understanding of how MSCs induce immunosuppresion can give us the rational needed for the most appropriate use of these cells.
Objectives: This study aimed to search for soluble factors produced by MSCs that can potentially be involved in the mechanism of immunosuppression. Methods: Mixed leucocyte reactions, were incubated in the absence or presence of 10% MSCs in a contact independent manner using a polycarbonate membrane (transwell) between MLRs and MSCs. After three or seven days, cultures were analysed using flow cytomety or submited to global gene expression analyses. Results: We found 672 mRNAs increased and 311 mRNAs decreased in at least 2X. 70% of mRNAs increased in MSCs in coculture were related to immune response. Of these, it was notorious the increased in mRNAs associated with antigen presentation via MHC I and II (8%), chemokine (9%), metabolism / transport of lipids (9%) and regulatory proteins induced by IFN-y (18 %).
The pathways most likely to be activated in MSCs after co-culture were IFN-y and IL-17. Among the 672 molecules increased in MSCs we choose COX-2 and the chemokines CCL8 e CXCL8 to evaluate their functions during the immunosuppression induced by MSCs. The use of indomethacin, a COX inhibitor, in co-cultures reversed the inhibitory effect of MSCs. Moreover, when separated from MLRs by a transwell of 0.5mM, which allows the passage of cells, we observed a greater suppression of those lymphocytes that migrated to the MSCs's niche, suggesting that chemokines are important in this process. Conclusions: After co-culture MSCs changed from an inactivated state, ''steady state'', to an activated state. This process induced their immunosuppressive phenotype, which involves COX2 and differents chemokines. The specific role of CCL8 and CXCL8 is under investigation.
Financial support: MS, CNPq, and FAPERJ. Background: Mesenchymal stromal cells (MSCs) possess immunomodulatory activity both in vitro and in vivo. However, little information is available about their function during the initiation of immunological responses through their interactions with
168
Poster Session I
